Diabetes Forecast

Few Diabetes Drug or Supply Shortages for now, Companies Say

By Miriam E. Tucker , ,

ivector/Bigstock

During the coronavirus pandemic, the American Diabetes Association (ADA) recommends that you refill all of your prescriptions now, to the extent allowed by your insurance company. Because of the new coronavirus (COVID-19), some insurers have eased rules about early refills, allowing you to get more medicine at one time—and avoid frequent trips to the pharmacy. And insulin manufacturers are offering financial assistance programs. (Learn more about getting your necessary medications and supplies.)

But many people with diabetes are wondering: Will those medications and supplies even be available? As of now, the answer is a tentative yes, although some products may be temporarily out of stock, and the situation could change.

Novo Nordisk
Products: Fiasp, Levemir, Novolin, Novolog, Tresiba, Victoza, and Xultophy insulins; Ozempic, Prandin, and Rybelsus blood glucose–lowering medications; GlucaGen hypoglycemia rescue drug
Supply Status: No current supply problems, and stock levels are normal. The company continues to monitor the situation.
Get updates here.

Eli Lilly & Co.
Products:
Basaglar, Humalog, and Humulin insulins; Jardiance and Trulicity blood glucose–lowering medications
Supply Status: Lilly does not currently anticipate shortages of any products, and insulin manufacturing sites in the United States and Europe have not been affected. While the company will not allow people to stockpile its medications, it will consider emergency requests on a case-by-case basis.
Get updates here.

Sanofi
Products:
Admelog, Apidra, Lantus, and Toujeo insulins; Adlyxin, Amaryl, and Soliqua blood glucose–lowering drugs
Supply Status:
There has been no impact on supply and manufacturing operations. Sanofi does not anticipate that its production of insulin products will be impacted by the COVID-19 pandemic.
Get updates here.

Dexcom
Product:
G6 CGM System
Supply Status: There have been no interruptions that would impact Dexcom’s ability to produce and supply its continuous glucose monitor (CGM). In terms of customer support, however, the company is limited in its ability to answer live calls, so expect wait times to be significantly longer than usual. The company requests that people contact the Customer Sales Support team for urgent requests only.
Get updates here.

Abbott
Products: FreeStyle Libre 14-Day System, FreeStyle blood glucose meters and test strips
Supply Status: There has been no impact on availability of Abbott’s diabetes care products due to COVID-19. The company continues to monitor the situation.
Get FreeStyle Libre and Abbott corporate updates.

Medtronic
Products: 630G and 670G insulin pump and CGM systems; Guardian Connect CGM system; Carelink software
Supply Status: The company is monitoring its supply and reports no significant impact on availability of Medtronic’s diabetes care products.
Get updates here.

Tandem
Products: T:slim X2 With Basal-IQ Technology and T:slim X2 With Control-IQ Technology
Supply Status: The company is experiencing higher than anticipated demand for supplies, so it’s asking some customers to accept substitutions of similar products to prevent delays in order fulfillment.
Get updates here.

Insulet
Product: Omnipod and Omnipod Dash insulin pumps
Supply Status: There has been no impact on availability of Insulet’s pumps; the company will continue to deliver products to customers without delays.
Get updates here.

 

PAID CONTENT

 
 
Take the Type 2
Diabetes Risk Test

PAID CONTENT